Rating Rationale
October 04, 2022 | Mumbai
Jubilant Ingrevia Limited
Rating reaffirmed; NCD withdrawn
 
Rating Action
Rs.100 Crore Non Convertible DebenturesCRISIL AA/Positive (Withdrawn)
Rs.400 Crore Commercial PaperCRISIL A1+ (Reaffirmed)
Note: None of the Directors on CRISIL Ratings Limited’s Board are members of rating committee and thus do not participate in discussion or assignment of any ratings. The Board of Directors also does not discuss any ratings at its meetings.
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has reaffirmed its ‘CRISIL A1+’ rating on the commercial paper programme of Jubilant Ingrevia Limited (JVL); the long-term rating on the non-convertible debentures (NCDs) has been withdrawn at the request of the company and on receipt of a no-dues certificate from the debenture holder. The withdrawal is in line with CRISIL Ratings policy on withdrawal of its ratings.

 

The reaffirmation of short-term rating reflects the expectation of continued strong operating performance over the medium term, supported by the addition of value-added products and capacity expansion plans across three business segments. Revenue growth is expected to remain healthy at 10-15% annually and operating margin will likely sustain above 15%, over the medium term. CRISIL Ratings also expects JVL will sustain its healthy financial risk profile, while undertaking material expansion across its businesses over the medium term, which will be prudently funded, ensuring robust debt protection metrics.

 

In fiscal 2022, the operating performance of JVL improved sharply owing to healthy cash accrual and consequent improvement in capital structure and debt protection metrics. Revenue grew by 42% year-on-year in fiscal 2022, driven by strong growth in the chemical intermediates (CI) segment, backed by favourable market conditions and commercialisation of capital expenditure (capex). Operating margin remained healthy at 16.8% in fiscal 2022 (17.6% in fiscal 2021) driven by a one-off gain in the CI segment given the favourable pricing environment for key products. The speciality chemicals (SC) and nutrition and health solutions (NHS) segments continued to grow steadily. In the first quarter of fiscal 2023, revenue growth was lower at 2% on a high base of the previous fiscal, with normalisation of realisations and lower acetic acid prices in the CI segment.

 

JVL repaid/prepaid about Rs 548 crore long-term debt over fiscal 2022 and first quarter of fiscal 2023 using healthy cash accrual; the outstanding gross debt of Rs 285 crore as on June 30, 2022, was entirely in the form of working capital borrowings. Consequently, debt protection metrics improved, with interest coverage ratio of 27.9 times in fiscal 2022 and 36.9 times in the first quarter of fiscal 2023 and net debt to earnings before interest, taxes, depreciation and amortisation (Ebitda) ratio of 0.2 time and 0.4 time, respectively. Financial risk profile will remain stable over the medium term even after factoring in sizeable ongoing and planned capex over fiscals 2022 and 2025, funded mainly through internal accrual. 

 

The rating continues to reflect the healthy business risk profile of JVL, supported by leading market position across most products, vertically integrated operations, and diversified revenue profile across business segments, geographies and end-user industries; the ratings also factor in the healthy financial risk profile. These strengths are partially offset by large working capital requirement and exposure to fluctuations in input prices as well as government policies.

Analytical Approach

CRISIL Ratings has combined the business and financial risk profiles of JVL and its subsidiaries, collectively referred to as the JVL group, as all the entities are under a common management and have operational linkages and fungible cash flow.

 

Please refer Annexure - List of entities consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description

Strengths:

  • Healthy business risk profile, driven by leading market position across most products and vertically integrated operations: JVL has an established market position across business segments, with portfolio offerings of more than 165 products. In the SC business, JVL is globally the lowest cost producer of pyridine-based derivative products, among the top two in pyridine and the leader in 14 pyridine derivatives. In the NHS business, it ranks among the top two manufacturers of vitamin B3 globally and among India’s largest in vitamin B4 (choline chloride) manufacturing. The company is one of the top two players in the acetic anhydride market globally and the leading producer of ethyl acetate. Furthermore, a healthy pipeline of over 60 new products will help sustain market position across business segments over the medium term.

 

JVL benefits from vertically integrated operations across the value chain, leading to cost competitiveness. About 45% of the CI segment volume was consumed by the SC segment and about 52% of the pyridine and picolines output of the SC segment was used in the NHS segment in fiscal 2022. Economies of scale derived from global presence of capacities, high level of integration in manufacturing, deep chemistry knowledge and continuous improvement in cost efficiency have historically supported operating profitability of JVL. Operating profitability remained healthy at 16.8% in fiscal 2022 and is expected to sustain above 15% over the medium term given the expanding portfolio of value-added products and ongoing capacity expansion for current products.

 

  • Diversified revenue profile: Revenue profile is diversified, with 28% derived from the high-margin SC segment in fiscal 2022, 16% from the NHS segment and the remaining 56% from the relatively low-contribution CI segment. Revenue diversity is further augmented by presence in the domestic and international markets, which accounted for 47% and 53%, respectively, of the total revenue in fiscal 2022. The company has a wide reach in the markets of North America and Europe. JVL has 1,400+ clients globally, with the top 10 customers accounting for 20-25% of the overall revenue.

 

Furthermore, JVL serves diverse end-user industries, such as pharmaceuticals (accounted for 37% of the revenue in fiscal 2022), agrochemicals (22%), nutrition (20%), and industrial segments such as paints, packaging and solvents (18%). This insulates JVL from downturn in any particular industry. Revenue grew 42% year-on-year in fiscal 2022, driven by strong growth in the CI segment, backed by favourable pricing scenario for key products, acetic anhydride and ethyl acetate. The revenue growth was lower at 2%, on a high base of previous fiscal, with normalisation of realisations and lower acetic acid prices in the CI segment. The diversified revenue stream and increasing focus on value-added products will support annual revenue growth of 10-15% over the medium term.

 

  • Healthy financial risk profile: The financial risk profile is supported by healthy capital structure and steady cash accrual. The company deleveraged in fiscal 2022 and its outstanding long-term debt was nil as on June 30, 2022. The net debt/Ebitda ratio improved to 0.2 time in fiscal 2022 and 0.4 time in the first quarter of fiscal 2023 from about 0.7 time in fiscal 2021. Other debt protection metrics were healthy, with adjusted interest coverage ratio of 27.9 times in fiscal 2022 and 36.9 times in the first quarter of fiscal 2023.

 

JVL has planned capex of ~Rs 2,050 crore over fiscals 2022 and 2025 towards expansion for diketene derivative products, expansion of facilities for crop protection chemicals, vitamin B3 products and acetic anhydride. The capex is progressing as per schedule and is expected to be funded through internal accrual, with minimal reliance on external borrowings; hence, gearing is likely to remain below 0.3 time while debt metrics will continue to be comfortable over the medium term.

 

Weaknesses:

  • Working capital-intensive operations: Operations are moderately working capital intensive, driven by high inventory levels, as the company maintains over two months of raw material and finished goods stock given its wide product portfolio. Cash collection policy is prudent, resulting in receivables of about 45 days. JVL benefits from good creditors support, thereby helping in working capital management. JVL’s working capital requirement is expected to increase owing to ramp-up in operations over the medium term.

 

  • Exposure to fluctuations in input prices and government policies: Fluctuations in the prices of acetic acid (key raw material for the CI segment) has led to volatility in operating margin. While input price is a pass-through, in case of any sharp increase or decrease in price, there could be some impact on the margin. Operating profitability will remain exposed to fluctuations in acetic acid prices as the CI segment is likely to account for about half of the overall revenue over the medium term.

 

Operations are exposed to government policies given the widespread international presence. For instance, JVL faced anti-dumping duty for its pyridine exports to China in 2015. Since then, the company has entered other geographies, thereby de-risking pyridine exposure to China. Furthermore, in November 2019, China terminated the anti-dumping duty. However, any adverse impact of government policies on revenue and profitability will remain a key rating sensitivity factor.

Liquidity: Strong

Net cash accrual is expected to be healthy at over Rs 550 crore per annum. Prepayment of the entire outstanding NCDs on June 3, 2022, resulted in nil debt obligation over the medium term. Also, the company has adequate cushion in its fund-based working capital limit, which was utilised at 35% on average over the 12 months through May 2022. Cash and bank balance was at Rs 57 crore as on June 30, 2022. Capex is expected to be largely funded through internal accrual, thereby reducing dependence on external debt over the medium term.

Rating Sensitivity factors

Downward factors

  • Sharp weakening of operating performance resulting in net cash accrual below Rs 350 crore on a sustained basis
  • Significant delay in ramp-up of new capacities or larger-than-expected debt availed for funding capex or acquisition, leading to deterioration in debt metrics with net debt/Ebitda over 1.75-1.90 times

About the Company

JVL is a global integrated life science products and innovative solutions provider serving pharmaceutical, nutrition, agrochemical and industrial clients with customised products and solutions that are cost effective and conform to premium quality standards.

 

With more than four decades of presence in the chemical industry and integrated operations, the company offers over 165 products ranging from speciality chemicals, advanced stage complex chemistry solutions, nutraceuticals, straight nutritional ingredients such as vitamin B3, premix solutions for animal and human nutrition, pyridine and picolines and acetyl range of products. It has 1,400 customers globally and five manufacturing facilities across Maharashtra, Gujarat and Uttar Pradesh.

 

In addition to own proprietary products, the company also offers contract development and manufacturing solutions ranging from route design to process development, process optimisation, scale-up and commercial manufacturing of intermediates for global customers across the pharmaceuticals, agrochemicals and other life science chemical industries.

 

As on June 30, 2022, the promoter and promoter group held 51.57% stake in JVL, foreign portfolio investors held 10.19%, individuals held 27.61% and the balance was held by others.

 

In the first quarter of fiscal 2023, the company reported revenue of Rs 1,166 crore (Rs 1,145 crore in the corresponding period of fiscal 2022) and net profit of Rs 79 crore (Rs 168 crore).

Key Financial Indicators (consolidated)

Particulars

Unit

2022

2021**

Revenue

Rs Crore

4,949

3,491

Profit after tax (PAT)

Rs Crore

477

316

PAT margin

%

9.6

9.1

Adjusted debt/adjusted networth

Times

0.09

0.29

Interest coverage

Times

27.90

8.85

**Includes 10 months financials of the life science division of Jubilant Pharmova Ltd (erstwhile, Jubilant Life Sciences Ltd) and two months financials of Jubilant Ingrevia Ltd

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings` complexity levels are assigned to various types of financial instruments and are included (where applicable) in the 'Annexure - Details of Instrument' in this Rating Rationale.

CRISIL Ratings will disclose complexity level for all securities - including those that are yet to be placed - based on available information. The complexity level for instruments may be updated, where required, in the rating rationale published subsequent to the issuance of the instrument when details on such features are available.

For more details on the CRISIL Ratings` complexity levels please visit www.crisilratings.com. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN

Name of

instrument

Date of allotment

Coupon rate (%)

Maturity

date

Issue size (Rs crore)

Complexity levels

Rating assigned

with outlook

NA

Commercial Paper

NA

NA

7-365 days

400

Simple

CRISIL A1+

INE700A07089

Non Convertible Debentures*

Jun-20

7.90%

Jun-23

100

Simple

Withdrawn

*Originally issued by Jubilant Pharmova Ltd (erstwhile Jubilant Life Sciences Ltd)

Annexure – List of entities consolidated

Names of
entities consolidated
Extent of
consolidation
Rationale for
consolidation
Jubilant Infrastructure Ltd Full Subsidiary, common management and operational linkages
Jubilant Lifesciences (USA) Inc Full Subsidiary, common management and operational linkages
Jubilant Lifesciences International Pte. Ltd Full Subsidiary, common management and operational linkages
Jubilant Lifesciences (Shanghai) Ltd Full Subsidiary, common management and operational linkages
Jubilant Lifesciences NV Full Subsidiary, common management and operational linkages
Jubilant Crop Protection Ltd (incorporated on June 2, 2021) Full Subsidiary, common management and operational linkages
Annexure - Rating History for last 3 Years
  Current 2022 (History) 2021  2020  2019  Start of 2019
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT   --   -- 06-05-21 CRISIL AA/Stable   --   -- --
Commercial Paper ST 400.0 CRISIL A1+ 30-04-22 CRISIL A1+ 06-05-21 CRISIL A1+   --   -- --
Non Convertible Debentures LT 100.0 Withdrawn 30-04-22 CRISIL AA/Positive 06-05-21 CRISIL AA/Stable   --   -- --
All amounts are in Rs.Cr.

    

Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating Criteria for Chemical Industry
CRISILs Criteria for Consolidation
Understanding CRISILs Ratings and Rating Scales
CRISILs Criteria for rating short term debt

Media Relations
Analytical Contacts
Customer Service Helpdesk

Aveek Datta
Media Relations
CRISIL Limited
M: +91 99204 93912
B: +91 22 3342 3000
AVEEK.DATTA@crisil.com

Prakruti Jani
Media Relations
CRISIL Limited
M: +91 98678 68976
B: +91 22 3342 3000
PRAKRUTI.JANI@crisil.com

Rutuja Gaikwad 
Media Relations
CRISIL Limited
B: +91 22 3342 3000
Rutuja.Gaikwad@ext-crisil.com


Anuj Sethi
Senior Director
CRISIL Ratings Limited
D:+91 44 6656 3100
anuj.sethi@crisil.com


Aditya Jhaver
Director
CRISIL Ratings Limited
D:+91 22 3342 3390
aditya.jhaver@crisil.com


Parth Shah
Manager
CRISIL Ratings Limited
B:+91 22 3342 3000
Parth.Shah@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited, an S&P Global Company)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a leading, agile and innovative global analytics company driven by its mission of making markets function better. 

It is India’s foremost provider of ratings, data, research, analytics and solutions with a strong track record of growth, culture of innovation, and global footprint.

It has delivered independent opinions, actionable insights, and efficient solutions to over 100,000 customers through businesses that operate from India, the US, the UK, Argentina, Poland, China, Hong Kong and Singapore.

It is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL's privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale ('report') that is provided by CRISIL Ratings Limited ('CRISIL Ratings'). To avoid doubt, the term 'report' includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, 'CRISIL Ratings Parties') guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee - more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to:
https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

 

 

CRISIL Ratings uses the prefix 'PP-MLD' for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html